Skip to content

Nasal Swab Home Collection Kit (NSHC Kit) Study

Self- and Parent/Guardian-Collection of Specimens for Rapid Influenza Nasal Swab Home Collection Kit (NSHC Kit) Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03813966
Enrollment
1181
Registered
2019-01-23
Start date
2019-02-07
Completion date
2020-06-30
Last updated
2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza Viral Infections

Brief summary

The purpose of this study is to demonstrate that persons over the age of 13 years can obtain a self-collected nasal swab reliably and safely for subsequent use in the diagnosis of influenza. Similarly, the purpose is to demonstrate that parents or guardians can safely and effectively collect nasal swab specimens from children, ages 0 through 12 years, and others needing assistance in doing so, and that these parent/guardian-collected nasal swabs can also be used in the diagnosis of influenza. Clinical performance of the swabs will be based on the comparison of the performance of the nasal swab that is self- or parent/guardian-collected to one collected from the same specimen donor by a skilled clinical coordinator and used in CLIA (Clinical Laboratory Improvement Amendments)-waived, rapid diagnostic test called Sofia Influenza A+B FIA (fluorescence immunoassay analyzer).

Interventions

DIAGNOSTIC_TESTSofia Influenza A+B FIA

The Nasal Swab Home Collection Kit (NSHC Kit) provides the materials and training needed for you to safely collect a nasal swab at home. The sample can then be delivered to a designated test site for influenza testing.

Sponsors

Quidel Corporation
CollaboratorINDUSTRY
University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Fever * Nasal Congestion * Rhinorrhea * Sore Throat * Cough

Exclusion criteria

* Unable to read and understand or refusal to sign the appropriate informed consent/assent forms * Refusal to complete the patient's demographic and medical history * Treatment with anti-influenza antivirals within the previous 7 days * Vaccinated by means of an influenza nasal spray/mist vaccine within the previous 7 days.

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic specificity of self-collected to technician collected nasal swab samples1 day (Participant); 17 weeks (Study length)Hypothesis tested is that self-collected nasal swab are as accurate as nasal swabs collected by a trained healthcare worker for the diagnosis of influenza by CLIA-waived, rapid diagnostic test called Quidel Sofia Influenza A+B Fluorescent Immunoassay. The investigators will specifically measure the specificity of self-collected specimens as compared to the clinical standard (trained healthcare worker collected specimen), estimating it using standard methods along with 95th% confidence intervals.
Diagnostic sensitivity of self-collected to technician collected nasal swab samples1 day (Participant); 17 weeks (Study length)Hypothesis tested is that self-collected nasal swab are as accurate as nasal swabs collected by a trained healthcare worker for the diagnosis of influenza by CLIA-waived, rapid diagnostic test called Quidel Sofia Influenza A+B Fluorescent Immunoassay. The investigators will specifically measure the sensitivity of self-collected specimens as compared to the clinical standard (trained healthcare worker collected specimen), estimating it using standard methods along with 95th% confidence intervals.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026